12,372 trials
Peanut Allergy
Primary: Percentage of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 600 mg in the Exit Double-Blind, Placebo-Controlled Food Challenge (DBPCFC) — 250; 5…
Grade B aGVHD · Grade C aGVHD · Grade D aGVHD
Primary: Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy — 69.1 percentage of participants — p=0.0003
Contraception
Primary: Number of Participants With Pregnancy — 20; 30 Participants
Outpatient Surgery · Pain, Postoperative
Primary: Narcotic Usage — 4.9; 2.0 Pills
Grade B Acute Graft Versus Host Disease · Grade C Acute Graft Versus Host Disease · Grade D Acute Graft Versus Host Disease
Primary: Overall Survival Rate Through Day 180 — 68.5 percentage of participants
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor — 16.5; 8.2 Months — p=0.0001
Attention Deficit Disorder
Primary: Attention-Deficit Hyperactivity Disorder Symptom Ratings Using the ADHD Rating Scale (ADHD-RS-IV) — 47.1; 46.1 score on a scale
Hypertension
Primary: Change in Average Sitting Diastolic Blood Pressure (DBP) Taken at Trough at the End of Treatment Compared to Baseline — -14.0; -10.9 mm Hg
Type 2 Diabetes Mellitus
Primary: Number of Participants With Hyperglycemia Relapse in the Experimental Group Compared to the Control Group — 41; 48 Participants
Antibiotic-associated Diarrhea
Primary: Number of Participants With the Occurrence of Antibiotic-associated Diarrhea (AAD) - Per Protocol (PP) Population — 4; 17 Participants — p=0.007
Rabies (Healthy Volunteers)
Primary: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titers Greater Than or Equal to (>=) 0.5 International Units Per Milliliter…
Common Variable Immunodeficiency (CVID), APDS / PASLI
Primary: Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 0; 2; 0 Participants
Knee Osteoarthritis
Primary: Determination of Optimal Procedure for Administering CNTX-4975-05 With Regards to Pain, Participant Satisfaction, and Investigator's Satisfaction — 17.18; 18.26; 16.48…
Lymphoma · Acute Lymphoblastic Leukemia
Primary: The Number of Participants With Non-Fatal DVT, PE, and CVST, and VTE-Related-Death — 31; 45 Participants — p=0.0403
Prematurity · Neurodevelopmental Disorder · Carnitine Deficiency
Primary: Time to Regain Birthweight in Infants Who Receive L-carnitine Supplementation Compared to Controls — 8.12; 8.4 days — p=<0.05